BioCentury | Feb 11, 2016
Distillery Therapeutics

Therapeutics: Downstream regulatory element antagonistic modulator (DREAM); ATP-dependent potassium channel (KATP)

...Huntington's disease (HD) In vitro, patient sample and mouse studies suggest inhibiting DREAM with NovoNorm repaglinide...
...increased survival compared with unmodified DREAM expression. In cell-based DREAM activity assays, the KATP inhibitor NovoNorm...
...of NovoNorm to treat HD and screening for selective DREAM inhibitors. Novo Nordisk A/S markets NovoNorm...
BioCentury | Dec 8, 2014
Clinical News

NovoNorm repaglinide regulatory update

...Japan approved an expanded label for Type II diabetes drug Surepost repaglinide to include combination therapy...
...monotherapy and as combination therapy with alpha-glucosidase inhibitors, thiazolidinediones or biguanides. Sumitomo has rights to Surepost...
...Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Product: NovoNorm repaglinide ( Prandin , Surepost ) ( SMP-508...
BioCentury | Jul 1, 2013
Company News

Novo Nordisk, Sun Pharmaceutical endocrine/metabolic news

...court ruling that a claim in a Novo Nordisk patent related to the use of repaglinide...
...2012. Prandin is a short-acting beta cell stimulating meglitinides and PrandiMet is a combination of repaglinide...
...subsidiary for generic repaglinide infringed Novo's U.S. Patent No. 6,677,358 covering the combination use of Prandin...
BioCentury | Mar 11, 2013
Clinical News

Surepost repaglinide regulatory update

...Health, Labor and Welfare (MHLW) approved an expanded label for Type II diabetes drug Surepost repaglinide...
...Surepost in combination with dipeptidyl peptidase-4 (DPP-4) inhibitors. Dainippon licensed rights to develop and market Surepost...
...Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Product: Surepost repaglinide ( NovoNorm , Prandin ) ( SMP-508...
BioCentury | Sep 13, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...of diabetes. Novo Nordisk A/S and Shionogi & Co. Ltd. market PrandiMet, a combination of repaglinide...
...and metformin, to treat diabetes. Novo Nordisk, Dainippon Sumitomo Pharma Co. Ltd. and Shionogi market NovoNorm...
BioCentury | Apr 23, 2012
Clinical News

Surepost regulatory update

...Health, Labor and Welfare (MHLW) to expand the label for Type II diabetes drug Surepost repaglinide...
...Surepost in combination with dipeptidyl peptidase-4 (DPP-4) inhibitors. Dainippon licensed rights to develop and market Surepost...
...CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Product: Surepost ( NovoNorm - EU, Prandin - U.S.) repaglinide ( SMP-508...
BioCentury | Apr 23, 2012
Company News

Novo Nordisk, Sun Pharmaceutical endocrine/metabolic news

...Ltd. subsidiary for generic repaglinide infringed a Novo patent covering the combination use of Prandin repaglinide...
...diabetes. Caraco filed a counterclaim noting that Novo's current use code for the use of Prandin...
...Prandin is a short-acting beta cell stimulating meglitinides while PrandiMet is a combination of repaglinide...
BioCentury | Apr 18, 2012
Politics & Policy

Supreme Court clarifies Hatch-Waxman counterclaim provision

...Laboratories Ltd. for generic repaglinide infringed a Novo patent covering the combination use of Prandin repaglinide...
...2018. Caraco filed a counterclaim noting that Novo's current use code for the use of Prandin...
...in worldwide sales of oral antidiabetics, including Prandin and PrandiMet. PrandiMet is a combination of repaglinide...
BioCentury | Oct 3, 2011
Company News

Novo Nordisk, Sun Pharmaceutical endocrine/metabolic news

...use code narratives. In 2005, Novo filed a suit alleging the ANDA for generic Prandin repaglinide...
...NYSE-A:CPD, Detroit, Mich.) subsidiary infringed Novo's U.S. Patent No. 6,677,358 covering the combination use of Prandin...
...sales of oral antidiabetics including Prandin and PrandiMet in 1H11. PrandiMet is a combination of repaglinide...
BioCentury | Sep 19, 2011
Clinical News

Glucagon-like peptide-1 endocrine/metabolic data

...plc (LSE:GSK; NYSE:GSK, London, U.K.); Starlix nateglinide from Novartis AG (NYSE:NVS; SIX:NOVN; Basel, Switzerland); Prandin repaglinide...
Items per page:
1 - 10 of 40